SGLT2 drug after first heart attack to reduce heart damage
Part of Heart & circulation clinical trials.
This Phase 2 trial tests whether an SGLT2 medicine started after a first STEMI heart attack can reduce ongoing heart muscle injury and scarring. It may help people who, based on heart imaging, have larger infarcts and ongoing microvascular damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 and this was your first STEMI (major heart attack).
- You had a successful emergency heart procedure called primary PCI, and you can consent.
- Your heart pumping is reduced (left ventricular ejection fraction under 50%) on imaging after the PCI.
- Your heart attack area is large enough (infarct size over 10% of the left-ventricle mass).
- Imaging shows microvascular blockage (MVO) over 10% of the infarct size.
- You must be able to safely have a cardiac MRI (no MRI contraindications or gadolinium contraindications).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether starting an SGLT-2 inhibitor around the time of a heart attack can reduce heart damage size and improve how the heart heals. It focuses on people with a high risk of developing heart failure and who are getting a procedure to open blocked heart arteries.
This study tests whether giving an SGLT2 inhibitor (a diabetes medicine that may also protect the heart) early after a heart attack can help shield the heart from damage. It is for people having a first-time STEMI heart attack who have adequate kidney function and stable blood pressure.
This study tests whether starting a beta blocker and an SGLT2 inhibitor right after a heart attack can help preserve heart function. It is for STEMI patients who have not yet been treated with these medicines.
This trial tests if combining GLP-1 and SGLT2 medications can reduce inflammation and improve heart function after a heart attack in people with type 2 diabetes and obesity. It looks for patients with a specific type of heart attack, elevated CRP levels, and preserved heart pumping ability.
This trial tests whether a diabetes medication, called an SGLT2 inhibitor, can reduce inflammation around heart arteries in people who have had a heart attack but do not have diabetes. The study uses a special heart scan to look at changes over time.
This trial tests whether a medicine called an SGLT2 inhibitor, which is usually used for diabetes, can help protect the brain and improve recovery when given soon after a stroke. It is for people who had a stroke within the last 3 days and have moderate to severe symptoms.
Hear when a new Myocardial Infarction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.